Humacyte, Inc. (HUMA): Capital Expenditures
$884.0K
Year ended 2025-12-31
$367.0K
Trailing 12 months to 2026-06-30
-5.5%
3-year compound annual growth
+22.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $884.0K | -43.8% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $1.57M | -31.1% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $2.28M | +117.6% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $1.05M | +376.4% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $220.0K | -30.8% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $318.0K | n/a | 2022-03-29, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 2025-12-31 | $884.0K | -43.8% |
| Aligos Therapeutics, Inc. (ALGS) | 2024-12-31 | $130.0K | +584.2% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $24.0K | +100.0% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $31.0K | -98.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $134.0K | -42.7% |
| Pluri Inc. (PLUR) | 2026-06-30 | $633.0K | -60.9% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $185.0K | -94.5% |
Compare HUMA, ALGS, SCNI, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗